Thomas Kruse, Herlev (DK); Mikael Kofod-Hansen, Broenshoej (DK); Martin Werner Borchsenius Muenzel, Broenshoej (DK); Henning Thoegersen, Farum (DK); Per Sauerberg, Farum (DK); Jakob Ewald, Koebenhavn N (DK); Carsten Behrens, Koebenhavn N (DK); Thomas Hoeg-Jensen, Broenshoej (DK); Vojtech Balsanek, Prague (CZ); Zuzana Drobnakova, Prague (CZ); Ladislav Droz, Prague (CZ); Miroslav Havranek, Prague (CZ); Vladislav Kotek, Prague (CZ); Milan Stengl, Klatovy (CZ); Ivan Snajdr, Prague (CZ); and Hana Drusanova, Kromeriz (CZ)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Jun. 16, 2023, as Appl. No. 18/210,763.
Application 18/210,763 is a continuation of application No. 17/500,242, filed on Oct. 13, 2021, granted, now 11,767,332.
Application 17/500,242 is a continuation of application No. 16/759,378, granted, now 11,186,595, issued on Nov. 30, 2021, previously published as PCT/EP2018/080650, filed on Nov. 8, 2018.
Claims priority of application No. 17200734 (EP), filed on Nov. 9, 2017; and application No. 18178294 (EP), filed on Jun. 18, 2018.
Prior Publication US 2023/0331745 A1, Oct. 19, 2023
